Alpha-Gal Syndrome
Tick-bite-induced allergy to mammalian products causing immune sensitization. MSC therapy targets the underlying immune dysregulation driving persistent reactions.
Alpha-gal syndrome (AGS) is an acquired allergy to alpha-galactose (alpha-gal), a carbohydrate found in the flesh of most mammals. Sensitization occurs through the bite of the Lone Star tick and certain other tick species, which carry alpha-gal in their saliva and trigger IgE antibody production against the molecule. Once sensitized, patients develop delayed allergic reactions — ranging from urticaria and gastrointestinal symptoms to anaphylaxis — hours after consuming mammalian meat or products.
AGS is increasingly recognized but frequently misdiagnosed due to the unusual delayed timing of reactions and its similarity to other food allergies. Current management is purely avoidance-based: patients must eliminate mammalian meat, dairy, gelatin, and many medications from their diet and lifestyle. There is no approved desensitization or curative therapy.
MSC therapy is being explored as an immune modulation strategy for AGS — targeting the IgE-mediated sensitization and underlying immune dysregulation rather than simply managing avoidance of triggers.
MSCs are potent modulators of IgE-mediated allergic responses. They suppress the Th2-dominant immune environment that drives IgE overproduction — expanding Treg populations, reducing IL-4 and IL-13 secretion, and shifting immune balance toward tolerance. This immune reprogramming mechanism has been studied in allergic asthma and food allergy models, where MSC infusion has reduced IgE titers and mast cell reactivity.
In AGS specifically, reducing the total IgE burden and restoring Th1/Th2 balance may reduce reaction severity, raise the threshold for triggering reactions, and allow gradual dietary reintroduction over time. While clinical trials in AGS specifically are in early phases, the immunological rationale parallels established MSC work in allergic and autoimmune conditions.
True Regen evaluates AGS patients with total IgE, specific anti-alpha-gal IgE, and a full allergy panel before treatment. Post-treatment immune monitoring tracks changes in IgE titers and Treg populations at 3, 6, and 12 months.
- Reduction in total and alpha-gal specific IgE titers
- Decreased severity and frequency of allergic reactions
- Potential tolerance recovery allowing cautious dietary reintroduction
- Reduced systemic Th2-mediated inflammation
- Improved quality of life and reduced dietary restriction burden
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.